2011 SAGS ANNUAL CONGRESS
14th Annual Congress of the South African Glaucoma Society
27 - 29 May 2011, Spier Wine Farm, Stellenbosch, Cape Town
click here for 2011 congress talks
click here for registration form
KEY SPEAKER
HIGHLIGHTS FROM THE 2010 SAGS CONGRESS
Alpine Heath Resort, Drakensberg, 28 - 30 May 2010
-
In the surgical treatment of Childhood Glaucoma, the first chance is the best chance and the right choice of surgical procedure is crucial.
-
Congenital glaucoma surgery results in 94 of cases after surgery with IOPs under 21mmHg, but 60% need topical medication.
-
Children on topical treatment for congenital glaucoma need naso-lacrinal occlusion because of high susceptibility to side effects.
-
Modulation of scarring after drainage surgery is the major determinant of IOP after surgery.
-
Phaco-emulsification after drainage surgery causes prolonged aqueous flare levels which need steroid treatment to prevent drainage failure.
-
A red eye after drainage surgery is a risk factor for failure.
-
Wound healing is prolonged and complex, treatment needs to prevent early scarring and address reversibility of scarring.
-
Anti-metabolites do not cause hypotony, but the surgical technique does! The surgeon needs to change the surgical technique
-
Use an air bubble for terminal glaucoma during filtration surgery. Air is 200x more compressable than water.
-
Do not set expectations pre-operatively, tell the patient of possible visual loss, complications due to filtering surgery. The patient needs to worry.
-
A single application of 5-FU 50mg/ml/5minutes significantly improves surgical survival for more than 5 years after surgery.
-
No patient progressed with IOPs consistently 14mmHg and under.
-
Novel anti-scarring compounds and drug delivery systems like the matrix-metall-proteinase enzyme inhibitor tablet releases a drug at therapeutic levels for over 30 days.
-
Avastin solution versus tablet release: the tablet release rate is at least 70x longer.
-
A cross-sectional study of black, white and coloured South Africans revealed a statistically significant difference between the ethnic groups, which needs adjusting glaucoma management practice.
In the surgical treatment of Childhood Glaucoma, the first chance is the best chance and the right choice of surgical procedure is crucial.
Congenital glaucoma surgery results in 94 of cases after surgery with IOPs under 21mmHg, but 60% need topical medication.
Children on topical treatment for congenital glaucoma need naso-lacrinal occlusion because of high susceptibility to side effects.
Modulation of scarring after drainage surgery is the major determinant of IOP after surgery.
Phaco-emulsification after drainage surgery causes prolonged aqueous flare levels which need steroid treatment to prevent drainage failure.
A red eye after drainage surgery is a risk factor for failure.
Wound healing is prolonged and complex, treatment needs to prevent early scarring and address reversibility of scarring.
Anti-metabolites do not cause hypotony, but the surgical technique does! The surgeon needs to change the surgical technique
Use an air bubble for terminal glaucoma during filtration surgery. Air is 200x more compressable than water.
Do not set expectations pre-operatively, tell the patient of possible visual loss, complications due to filtering surgery. The patient needs to worry.
A single application of 5-FU 50mg/ml/5minutes significantly improves surgical survival for more than 5 years after surgery.
No patient progressed with IOPs consistently 14mmHg and under.
Novel anti-scarring compounds and drug delivery systems like the matrix-metall-proteinase enzyme inhibitor tablet releases a drug at therapeutic levels for over 30 days.
Avastin solution versus tablet release: the tablet release rate is at least 70x longer.
A cross-sectional study of black, white and coloured South Africans revealed a statistically significant difference between the ethnic groups, which needs adjusting glaucoma management practice.
Congratulations to the new President of the South African Glaucoma Society - Dr Japie Vos as well as the newly appointed Vice-President - Prof Andries Stulting.
Mission Statement and Goals of the South African Glaucoma Society (SAGS)
To optimise the quality of glaucoma care in South Africa through communication and co-operation amongst General Practitioners, Optometrists, Ophthalmologists and Glaucomatologists with Glaucoma Industries, Glaucoma Patient Organizations and all other major players in the glaucoma field. We have a shared goal: The Quality of Life of the Glaucoma Patient.
Governance and Responsibility of South African Glaucoma Society:
The Executive Committee, the President of SAGS and 6 Executive Members convene the Annual General Meeting at the annual SAGS Congress, have regular executive meetings, co-operate with International Glaucoma Societies in America (AGS), Europe (EGS), Africa (SAG), Australia and the Far East (SEAG), co-operate with Glaucoma Industries, adhere to the World Glaucoma Association (WGA) Code of Practice, guidelines for conduct of meetings, direct profits from official meetings go to the Society (www.glaucom.com) and communicate via electronic means of email. Secretary to SAGS: Charmaine Watkins - contact details: tel:
Membership Criteria:
Members of South African Glaucoma Society (SAGS) are either full member (private practice or academic); associate member (resident or student member); corresponding member, honorary or life member. Members are committed to the mission of SAGS, to action needed to realise these goals and to active communication.
Patient Information
The goal of glaucoma treatment is the preservation of visual function and quality of life, with minimal or no side effects, with minimal disruption to the normal activities of a glaucoma patient, at a sustainable cost to the patient and the health provider
Read more »
Doctors Information
The South African Glaucoma Society aims to optimise the quality of glaucoma care in South Africa. Our management goal is the preservation of visual function adequate to the individual needs with minimal or no side effects, for the expected life time of the patient, without any disruption of his/her normal activities, at a sustainable cost.
Read more »